Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866.

ABSTRACT: Glioblastoma (GBM) is a prevalent brain cancer with notorious aggressiveness in adults. Standard treatment for GBM includes surgery, radiation, and administration of Temozolomide (TMZ). However, the TMZ resistance during chemotherapy poses a significant challenge. In the recent study a patient-derived TMZ-resistant GBM cell line, we found that Olaparib, a PARP inhibitor, exerted a significant tumor inhibition effect. However, the required dosage appeared to be beyond current clinical applicable levels. From a transcriptome analysis screen, a drastic upregulation of nicotinamide phosphoribosyltransferase (NAMPT) was validated in tumor cells survived from Olaparib treatments. The increased level of intracellular NAD + was sufficient to increase the cell survival from Olaparib and TMZ exposur

SUBMITTER: Sha X 

PROVIDER: S-EPMC12261764 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature